Literature DB >> 11480880

Clinical features of treatment-resistant depression.

S G Kornstein1, R K Schneider.   

Abstract

As many as 30% to 40% of patients with major depressive disorder are unresponsive to a trial of antidepressant medication. Many patients labeled with treatment-resistant depression actually have pseudoresistance, in that they have been inadequately treated or are misdiagnosed. Others may have unrecognized comorbid psychiatric or general medical conditions that contribute to treatment resistance. Variables such as gender, family history, age at onset, severity, and chronicity have also been evaluated as possible risk factors for treatment-resistant depression. This article reviews the current literature regarding the clinical characteristics of treatment-resistant depression, with particular attention to the relevance of these factors for clinical decision making.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11480880

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  39 in total

1.  Association between suicide death and concordance with benzodiazepine treatment guidelines for anxiety and sleep disorders.

Authors:  Jennifer M Boggs; Richard C Lindrooth; Catherine Battaglia; Arne Beck; Debra P Ritzwoller; Brian K Ahmedani; Rebecca C Rossom; Frances L Lynch; Christine Y Lu; Beth E Waitzfelder; Ashli A Owen-Smith; Gregory E Simon; Heather D Anderson
Journal:  Gen Hosp Psychiatry       Date:  2019-11-17       Impact factor: 3.238

2.  Prevalence of obstructive sleep apnea in suicidal patients with major depressive disorder.

Authors:  William V McCall; Ruth M Benca; Meredith E Rumble; Doug Case; Peter B Rosenquist; Andrew D Krystal
Journal:  J Psychiatr Res       Date:  2019-06-19       Impact factor: 4.791

3.  Tackling partial response to depression treatment.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

4.  Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression.

Authors:  S Anttila; K Huuhka; M Huuhka; R Rontu; K M Mattila; E Leinonen; T Lehtimäki
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

5.  Four maternal characteristics determine the 12-month course of chronic severe postpartum depressive symptoms.

Authors:  Sheehan D Fisher; Dorothy K Sit; Amy Yang; Jody D Ciolino; Jackie K Gollan; Katherine L Wisner
Journal:  Depress Anxiety       Date:  2019-01-15       Impact factor: 6.505

6.  Translating Science Into Service: Lessons Learned From the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study.

Authors:  Norman Sussman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 7.  Escitalopram: a pharmacoeconomic review of its use in depression.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  Feasibility, safety, acceptability, and preliminary efficacy of measurement-based care depression treatment for HIV patients in Bamenda, Cameroon.

Authors:  Brian W Pence; Bradley N Gaynes; Julius Atashili; Julie K O'Donnell; Dmitry Kats; Kathryn Whetten; Alfred K Njamnshi; Tabenyang Mbu; Charles Kefie; Shantal Asanji; Peter Ndumbe
Journal:  AIDS Behav       Date:  2014-06

9.  Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?

Authors:  Márcia Calheiros Chaves Silva; Caren Nádia Soares de Sousa; Luis Rafael Leite Sampaio; Naiara Coelho Ximenes; Paulo Victor Pontes Araújo; Jéssica Calheiros da Silva; Suzyana Lima de Oliveira; Francisca Cléa Florenço Sousa; Danielle Silveira Macêdo; Silvânia Maria Mendes Vasconcelos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-16       Impact factor: 3.000

10.  Economic implications of treatment-resistant depression among employees.

Authors:  Paul Greenberg; Patricia K Corey-Lisle; Howard Birnbaum; Maryna Marynchenko; Ami Claxton
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.